Trial reportClinical and translational medicine2026
Circulating tumour DNA to guide rechallenge with cetuximab plus irinotecan in RAS/BRAF wild-type metastatic colorectal cancer: A nonrandomised clinical trial.
Trial report in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04224415 (Re-challenge of Anti-EGFR Agents for Chinese Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Re-challenge of Anti-EGFR Agents for Chinese Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMutant subclones driving anti-EGFR resistance may progressively decline after therapy cessation, potentially reversing resistance to EGFR-targeted treatment. We therefore examined whether rechallenge with cetuximab plus irinotecan is active and tolerable in patients selected by circulating tumour DNA (ctDNA) testing, focusing on metastatic colorectal cancer (mCRC) with RAS/BRAF wild-type (WT) status.
methodsThis single-arm, Phase II clinical trial enrolled patients between November 2019 and February 2025. Eligible patients had histologically confirmed RAS/BRAF WT mCRC at diagnosis, prior cetuximab-based first-line therapy with clinical benefit, radiographic progression while on cetuximab or within 3 months after stopping it, subsequent progression after at least 1 additional systemic therapy, a cetuximab washout period of at least 4 months, and ctDNA-confirmed RAS/BRAF WT status before rechallenge. Each 2-week cycle delivered intravenous cetuximab (500 mg/m
resultsThis study enrolled 36 patients. Partial response was seen in 6 patients (16.7%), stable disease in 10 (27.8%), and progressive disease in 16 (44.4%); the remaining 4 patients were unevaluable due to early loss to follow-up. The ORR reached 16.7% (95% CI: 7.9-31.9), with a disease control rate of 44.4% (95% CI: 29.5-60.4). The median PFS and OS were 3.9 months (95% CI: 3.1-4.7) and 13.0 months (95% CI: 8.1-17.9). Multivariate Cox regression analyses identified screening time interval (STI) as an independent predictor of PFS (HR = 0.93 per additional month; 95% CI: 0.88-0.99). TRAEs of grade 3-4 were uncommon and clinically manageable.
conclusionsThese findings suggest that ctDNA-guided rechallenge with cetuximab plus irinotecan may offer benefit in RAS/BRAF WT mCRC, with STI potentially informing patient selection. Nevertheless, further validation in larger randomised trials is warranted.
trial registrationClinicalTrials.gov Identifier: NCT04224415. GRAPHICAL HEADLIGHTS: RAS/BRAF wild-type status confirmed by ctDNA may identify candidates for cetuximab rechallenge. A longer screening time interval was associated with improved progression-free survival. These hypothesis-generating findings warrant validation in larger randomised trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.